Drugs Made In America Acquisition Corp., a blank check company incorporated in the Cayman Islands and focused on the pharmaceutical industry, has released its Form 10-Q report for the first quarter of 2025. The report provides insights into the company's financial performance and operational strategies following its recent IPO.
Financial Highlights
Net Income: $1.25 million
Basic and diluted net income per redeemable ordinary share: $0.05
Business Highlights
Company Overview
Drugs Made In America Acquisition Corp. is a blank check company incorporated in the Cayman Islands, focusing on mergers, share exchanges, asset acquisitions, and other business combinations, primarily targeting the pharmaceutical industry.
IPO and Fundraising
The company successfully completed its Initial Public Offering (IPO) on January 29, 2025, raising $200 million through the sale of 20 million units. An additional $30 million was raised through the exercise of the over-allotment option by underwriters.
Private Placement
Simultaneously with the IPO, the company conducted a private placement with its sponsor, raising $4 million through the sale of 400,000 units. An additional $300,000 was raised through the sale of 30,000 units during the over-allotment option exercise.
Trust Account
A total of $231.15 million from the IPO and private placement proceeds was placed in a trust account to be used for future business combinations.
Operational Strategy
The company intends to use the funds from the trust account to complete an initial business combination within 15 months from the IPO closing date, with potential extensions up to 21 months.
Future Outlook
The management plans to focus on identifying and evaluating target businesses in the pharmaceutical sector, leveraging the funds raised to facilitate a successful business combination.
SEC Filing: